Investor Relations

Latest News

Mar 20, 2023

DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

View Press Release

Mar 13, 2023

DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 6, 2023

DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

View All News

DiaMedica Corporate Presentation

View Presentation

Mar 29, 2023 8:00 am EDT

Fourth Quarter 2022 Financial Results Conference Call

View Event Add to Calendar View All

May 17, 2023 1:00 pm CDT

Annual General and Special Meeting of Shareholders

Add to Calendar View All

May 31, 2023

20th Annual Craig-Hallum Institutional Investor Conference

View All

Most Recent Business Quarterly Update

View ReMEDy2 Trial Update

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

View Board of Directors

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
301 Carlson Parkway
Suite 210
Minnetonka, MN 55305